Abstract
Progressive Supranuclear Palsy (PSP) is a progressive neurodegenerative syndrome characterized by supranuclear palsy, postural instability, and mild dementia. Neuropathologically, PSP is a four-repeat tauopathy, defined by the accumulation of neurofibrillary tangles and tufted astrocytes. Etiology remains elusive, but genetic background has a key-role in the disease pathogenesis. Recent studies have reported high familial aggregation in PSP patients, and it has been widely demonstrated that Microtuble Associated Protein Tau (MAPT) gene mutations are causative of monogenic autosomal dominant PSP. In sporadic cases, genetic advances have further confirmed the role of MAPT in increasing disease risk, and the H1 MAPT haplotype has been consistently associated with PSP, while the H2 haplotype seems protective. Conversely, no major environmental risk factors have been reported so far. A proper evaluation of known susceptibility factors related to PSP pathogenesis may help in defining neuroprotective therapeutic approaches.
Keywords: Progressive Supranuclear Palsy, Microtuble Associated Protein Tau, Tau, genetics, mutations, polymorphisms, PSP, neurodegenerative syndrome, mild dementia, four-repeat tauopathy
Current Medicinal Chemistry
Title: Genetic Bases of Progressive Supranuclear Palsy: The MAPT Tau Disease
Volume: 18 Issue: 17
Author(s): Barbara Borroni, Chiara Agosti, Enrico Magnani, Monica Di Luca and Alessandro Padovani
Affiliation:
Keywords: Progressive Supranuclear Palsy, Microtuble Associated Protein Tau, Tau, genetics, mutations, polymorphisms, PSP, neurodegenerative syndrome, mild dementia, four-repeat tauopathy
Abstract: Progressive Supranuclear Palsy (PSP) is a progressive neurodegenerative syndrome characterized by supranuclear palsy, postural instability, and mild dementia. Neuropathologically, PSP is a four-repeat tauopathy, defined by the accumulation of neurofibrillary tangles and tufted astrocytes. Etiology remains elusive, but genetic background has a key-role in the disease pathogenesis. Recent studies have reported high familial aggregation in PSP patients, and it has been widely demonstrated that Microtuble Associated Protein Tau (MAPT) gene mutations are causative of monogenic autosomal dominant PSP. In sporadic cases, genetic advances have further confirmed the role of MAPT in increasing disease risk, and the H1 MAPT haplotype has been consistently associated with PSP, while the H2 haplotype seems protective. Conversely, no major environmental risk factors have been reported so far. A proper evaluation of known susceptibility factors related to PSP pathogenesis may help in defining neuroprotective therapeutic approaches.
Export Options
About this article
Cite this article as:
Borroni Barbara, Agosti Chiara, Magnani Enrico, Di Luca Monica and Padovani Alessandro, Genetic Bases of Progressive Supranuclear Palsy: The MAPT Tau Disease, Current Medicinal Chemistry 2011; 18 (17) . https://dx.doi.org/10.2174/092986711795933722
DOI https://dx.doi.org/10.2174/092986711795933722 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reduced Mitochondrial Activity is Early and Steady in the Entorhinal Cortex but it is Mainly Unmodified in the Frontal Cortex in Alzheimer's Disease
Current Alzheimer Research Cardiovascular Effects of Antiretroviral Drugs: Clinical Review
Cardiovascular & Hematological Disorders-Drug Targets Bromelain Degrades Aβ1-42 Monomers and Soluble Aggregates: An In Vitro Study in Cerebrospinal Fluid of Alzheimer’s Disease Patients
Current Alzheimer Research Preface: Highlights of Recent Progress in Alzheimers Disease Research [ Hot Topics in Alzheimers Disease Research (Guest Editor: Debomoy K. Lahiri)]
Current Drug Targets Preface [Hot Topic: Advances in the Four Pillars of Alzheimer Disease Research: Pathobiology, Genetics, Diagnosis, and Treatment (Debomoy K. Lahiri)]
Current Alzheimer Research Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Implication of Oncogenic Signaling Pathways as a Treatment Strategy for Neurodegenerative Disorders – Contemporary Approaches
CNS & Neurological Disorders - Drug Targets Advances in Metabonomics on Infectious Diseases
Current Metabolomics Novel Therapies for Schizophrenia: Understanding the Glutamatergic Synapse and Potential Targets for Altering N-methyl-D-aspartate Neurotransmission
Recent Patents on CNS Drug Discovery (Discontinued) Advances in Medicinal Plants with Effects on Anxiety Behavior Associated to Mental and Health Conditions
Current Medicinal Chemistry The Role of the RhoA/rho-kinase Pathway in Pulmonary Hypertension
Current Drug Discovery Technologies Biochemical Markers in CSF of ALS Patients
Current Medicinal Chemistry GABAergic Modulation in Diabetic Encephalopathy-Related Depression
Current Pharmaceutical Design Drug Treatment of Metabolic Syndrome
Current Clinical Pharmacology Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors
Current Medicinal Chemistry Can Diet and Physical Activity Limit Alzheimer's Disease Risk?
Current Alzheimer Research Chinese Herbs for Dementia Diseases
Mini-Reviews in Medicinal Chemistry Propofol Promotes Blood-Brain Barrier Breakdown and Heat Shock Protein (HSP 72 kd) Activation in the Developing Mouse Brain
CNS & Neurological Disorders - Drug Targets Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry Disease State, Age, Sex, and Post-Mortem Time-Dependent Expression of Proteins in AD vs. Control Frontal Cortex Brain Samples
Current Alzheimer Research